Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice

Robin L Brey, A. A. Amato, K. Kagan-Hallet, C. B. Rhine, Christian Stallworth

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Abnormal neurological functioning similar to that seen in systemic lupus erythematosus (SLE) patients is detectable in an SLE-prone murine strain (MRL/1pr) by 8-10 weeks and is severe by 18 weeks of age. The purpose of this study was to evaluate the effectiveness of murine anti-intercellular adhesion molecule-1 (ICAM-1) in suppressing neurological disease in MRL/1pr mice. Beginning at 6 weeks of age, five MRL/1pr mice received 5 weekly intraperitoneal injections of anti-ICAM-1-containing culture supernatant in phosphate-buffered saline (PBS) whereas four animals were treated with non-anti-ICAM-1 containing supernatant in PBS. A decline in neurological functioning began in control mice by 10 weeks, but anti-ICAM-1 treated mice remained normal throughout the study. All control mice had vasculitic skin lesions by 14 weeks of age whereas none of the anti-ICAM-1 treated mice ever developed skin lesions. Nerve conduction studies performed on all mice prior to sacrifice showed sciatic compound motor action potentials of anti-ICAM-1 treated mice that were of higher amplitude and shorter latency than those of controls. Inflammation in the sciatic nerve was more common in control mice. Brain histology revealed a similar degree of choroid plexus inflammation in both groups. Our study demonstrated that anti-ICAM-1 was effective in suppressing neurological abnormalities in MRL/1pr mice and may potentially be useful therapy in human SLE.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
JournalLupus
Volume6
Issue number8
StatePublished - 1997

Fingerprint

Central Nervous System Diseases
Peripheral Nervous System Diseases
Intercellular Adhesion Molecule-1
Antibodies
Systemic Lupus Erythematosus
Therapeutics
Phosphates
Inflammation
Skin
Choroid Plexus
Neural Conduction
Sciatic Nerve
Intraperitoneal Injections
Action Potentials
Histology

Keywords

  • Intercellular adhesion molecule-1
  • MRL/1pr mice
  • Nerve conduction studies
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. / Brey, Robin L; Amato, A. A.; Kagan-Hallet, K.; Rhine, C. B.; Stallworth, Christian.

In: Lupus, Vol. 6, No. 8, 1997, p. 645-651.

Research output: Contribution to journalArticle

Brey, Robin L ; Amato, A. A. ; Kagan-Hallet, K. ; Rhine, C. B. ; Stallworth, Christian. / Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. In: Lupus. 1997 ; Vol. 6, No. 8. pp. 645-651.
@article{e35761a5e7be4f62b04aa072480da993,
title = "Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice",
abstract = "Abnormal neurological functioning similar to that seen in systemic lupus erythematosus (SLE) patients is detectable in an SLE-prone murine strain (MRL/1pr) by 8-10 weeks and is severe by 18 weeks of age. The purpose of this study was to evaluate the effectiveness of murine anti-intercellular adhesion molecule-1 (ICAM-1) in suppressing neurological disease in MRL/1pr mice. Beginning at 6 weeks of age, five MRL/1pr mice received 5 weekly intraperitoneal injections of anti-ICAM-1-containing culture supernatant in phosphate-buffered saline (PBS) whereas four animals were treated with non-anti-ICAM-1 containing supernatant in PBS. A decline in neurological functioning began in control mice by 10 weeks, but anti-ICAM-1 treated mice remained normal throughout the study. All control mice had vasculitic skin lesions by 14 weeks of age whereas none of the anti-ICAM-1 treated mice ever developed skin lesions. Nerve conduction studies performed on all mice prior to sacrifice showed sciatic compound motor action potentials of anti-ICAM-1 treated mice that were of higher amplitude and shorter latency than those of controls. Inflammation in the sciatic nerve was more common in control mice. Brain histology revealed a similar degree of choroid plexus inflammation in both groups. Our study demonstrated that anti-ICAM-1 was effective in suppressing neurological abnormalities in MRL/1pr mice and may potentially be useful therapy in human SLE.",
keywords = "Intercellular adhesion molecule-1, MRL/1pr mice, Nerve conduction studies, Systemic lupus erythematosus",
author = "Brey, {Robin L} and Amato, {A. A.} and K. Kagan-Hallet and Rhine, {C. B.} and Christian Stallworth",
year = "1997",
language = "English (US)",
volume = "6",
pages = "645--651",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice

AU - Brey, Robin L

AU - Amato, A. A.

AU - Kagan-Hallet, K.

AU - Rhine, C. B.

AU - Stallworth, Christian

PY - 1997

Y1 - 1997

N2 - Abnormal neurological functioning similar to that seen in systemic lupus erythematosus (SLE) patients is detectable in an SLE-prone murine strain (MRL/1pr) by 8-10 weeks and is severe by 18 weeks of age. The purpose of this study was to evaluate the effectiveness of murine anti-intercellular adhesion molecule-1 (ICAM-1) in suppressing neurological disease in MRL/1pr mice. Beginning at 6 weeks of age, five MRL/1pr mice received 5 weekly intraperitoneal injections of anti-ICAM-1-containing culture supernatant in phosphate-buffered saline (PBS) whereas four animals were treated with non-anti-ICAM-1 containing supernatant in PBS. A decline in neurological functioning began in control mice by 10 weeks, but anti-ICAM-1 treated mice remained normal throughout the study. All control mice had vasculitic skin lesions by 14 weeks of age whereas none of the anti-ICAM-1 treated mice ever developed skin lesions. Nerve conduction studies performed on all mice prior to sacrifice showed sciatic compound motor action potentials of anti-ICAM-1 treated mice that were of higher amplitude and shorter latency than those of controls. Inflammation in the sciatic nerve was more common in control mice. Brain histology revealed a similar degree of choroid plexus inflammation in both groups. Our study demonstrated that anti-ICAM-1 was effective in suppressing neurological abnormalities in MRL/1pr mice and may potentially be useful therapy in human SLE.

AB - Abnormal neurological functioning similar to that seen in systemic lupus erythematosus (SLE) patients is detectable in an SLE-prone murine strain (MRL/1pr) by 8-10 weeks and is severe by 18 weeks of age. The purpose of this study was to evaluate the effectiveness of murine anti-intercellular adhesion molecule-1 (ICAM-1) in suppressing neurological disease in MRL/1pr mice. Beginning at 6 weeks of age, five MRL/1pr mice received 5 weekly intraperitoneal injections of anti-ICAM-1-containing culture supernatant in phosphate-buffered saline (PBS) whereas four animals were treated with non-anti-ICAM-1 containing supernatant in PBS. A decline in neurological functioning began in control mice by 10 weeks, but anti-ICAM-1 treated mice remained normal throughout the study. All control mice had vasculitic skin lesions by 14 weeks of age whereas none of the anti-ICAM-1 treated mice ever developed skin lesions. Nerve conduction studies performed on all mice prior to sacrifice showed sciatic compound motor action potentials of anti-ICAM-1 treated mice that were of higher amplitude and shorter latency than those of controls. Inflammation in the sciatic nerve was more common in control mice. Brain histology revealed a similar degree of choroid plexus inflammation in both groups. Our study demonstrated that anti-ICAM-1 was effective in suppressing neurological abnormalities in MRL/1pr mice and may potentially be useful therapy in human SLE.

KW - Intercellular adhesion molecule-1

KW - MRL/1pr mice

KW - Nerve conduction studies

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0030696153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030696153&partnerID=8YFLogxK

M3 - Article

C2 - 9364423

AN - SCOPUS:0030696153

VL - 6

SP - 645

EP - 651

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -